Quantcast
Last updated on April 25, 2014 at 1:22 EDT

Latest Questcor Pharmaceuticals Inc. Stories

2014-04-24 08:33:24

ANAHEIM, Calif., April 24, 2014 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (Nasdaq: QCOR) today announced that it will release first quarter 2014 financial results on Monday, April 28, 2014 after the close of the U.S. financial markets. In light of Questcor's pending merger with Mallinckrodt plc, the Company will not be hosting a conference call to discuss its financial results. Further details will be available in a Form 10-Q filing to be filed with the Securities and Exchange...

2014-04-21 08:26:07

- Clinical results appear to correlate with reduction in anti-PLA2R antibodies ANAHEIM, Calif., April 21, 2014 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (Nasdaq: QCOR) today announced that results from an investigator-initiated clinical study involving two major academic research centers examining the dosing and effectiveness of H.P. Acthar® Gel (repository corticotropin) in 20 patients with nephrotic syndrome due to idiopathic membranous nephropathy (iMN) have been published in the...

2014-04-17 08:28:50

HAYWARD, Calif., April 17, 2014 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today announced that it is partnering with the National Kidney Foundation (NKF) to become a National Sponsor of Kidney Walk, the country's largest walk to raise money and awareness for kidney disease. Through this partnership, Questcor will support more than 85 Kidney Walks across the country. The nationwide series is comprised of community events that call attention to kidney disease and the need...

2014-04-14 12:33:48

Editor Note: For more information about this release, please scroll to bottom. NEW YORK, April 14, 2014 /PRNewswire/ -- Today, Analysts Review released its analysts' notes regarding Questcor Pharmaceuticals Inc. (NASDAQ: QCOR), Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), Eli Lilly and Co. (NYSE: LLY), Medtronic Inc. (NYSE: MDT) and Alexion Pharmaceuticals Inc. (NASDAQ: ALXN). Private wealth members receive these notes ahead of publication. To reserve complementary...

2014-04-11 12:23:59

NEW YORK, April 11, 2014 /PRNewswire/ -- Imperva, Inc. Lifshitz & Miller announces that it is investigating potential claims against the board of Imperva, Inc. ("IMPV"). On April 9, 2014, Imperva announced that it expects to report total revenue for the first quarter of 2014 in the range of $31.0 million to $31.5 million compared to the company's prior guidance of total revenue in the range of $36.0 million to $37.0 million. For more information about our investigation,...

2014-04-09 12:27:45

NEW YORK, April 9, 2014 /PRNewswire/ -- Levi & Korsinsky is investigating the Board of Directors of Questcor Pharmaceuticals Inc. ("Questcor" or "the Company") (NasdaqGS: QCOR) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Mallinckrodt. http://photos.prnewswire.com/prnvar/20120409/MM84375LOGO Click here to learn more about the action http://zlk.9nl.com/questcor, or call: 877-363-5972. There is no cost or...

2014-04-07 12:34:18

NEW YORK, April 7, 2014 /PRNewswire/ -- Bernstein Liebhard LLP is investigating whether the Board of Directors of Questcor Pharmaceuticals, Inc. ("Questcor" or the "Company") (NASDAQ: QCOR) breached its fiduciary duty to its shareholders in agreeing to sell Questcor to Mallinckrodt public limited company ("Mallinckrodt"). http://photos.prnewswire.com/prnvar/20120202/MM47134LOGO Under the terms of the agreement, Questcor shareholders will receive $30.00 in cash and 0.897 Mallinckrodt...

2014-04-07 08:29:56

ANAHEIM, Calif., April 7, 2014 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (Nasdaq: QCOR) today announced that its Board of Directors has declared a quarterly cash dividend of $0.30 per share ($1.20 per share on an annual basis). The dividend will be paid on or about July 8, 2014 to shareholders of record at the close of business on July 1, 2014. The Company previously announced the declaration of a quarterly cash dividend of $0.30 per share which will be paid on or about April...

2014-04-07 08:29:44

--Questcor Shareholders Receive $30.00 in Cash and 0.897 Mallinckrodt Shares for Each Share of Questcor Common Stock They Own-- DUBLIN and ANAHEIM, Calif., April 7, 2014 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceuticals company, and Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR), a high-growth biopharmaceutical company, today announced that they have entered into a definitive merger agreement under which Mallinckrodt will acquire Questcor in a transaction...

2014-03-20 08:30:43

- Company's total commitment to Endowment reaches $250,000 - HAYWARD, Calif., March 20, 2014 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today announced that it is contributing $175,000 to the Child Neurology Society and Child Neurology Foundation to further endow the Philip R. Dodge Young Investigator Award. The Dodge Award, named after Dr. Philip Rogers Dodge, one of the modern founders of the specialty of pediatric neurology, recognizes a promising young...